These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 33502920)

  • 1. Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma.
    Kumar R; Smith KS; Deng M; Terhune C; Robinson GW; Orr BA; Liu APY; Lin T; Billups CA; Chintagumpala M; Bowers DC; Hassall TE; Hansford JR; Khuong-Quang DA; Crawford JR; Bendel AE; Gururangan S; Schroeder K; Bouffet E; Bartels U; Fisher MJ; Cohn R; Partap S; Kellie SJ; McCowage G; Paulino AC; Rutkowski S; Fleischhack G; Dhall G; Klesse LJ; Leary S; Nazarian J; Kool M; Wesseling P; Ryzhova M; Zheludkova O; Golanov AV; McLendon RE; Packer RJ; Dunham C; Hukin J; Fouladi M; Faria CC; Pimentel J; Walter AW; Jabado N; Cho YJ; Perreault S; Croul SE; Zapotocky M; Hawkins C; Tabori U; Taylor MD; Pfister SM; Klimo P; Boop FA; Ellison DW; Merchant TE; Onar-Thomas A; Korshunov A; Jones DTW; Gajjar A; Ramaswamy V; Northcott PA
    J Clin Oncol; 2021 Mar; 39(7):807-821. PubMed ID: 33502920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03).
    Gajjar A; Robinson GW; Smith KS; Lin T; Merchant TE; Chintagumpala M; Mahajan A; Su J; Bouffet E; Bartels U; Schechter T; Hassall T; Robertson T; Nicholls W; Gururangan S; Schroeder K; Sullivan M; Wheeler G; Hansford JR; Kellie SJ; McCowage G; Cohn R; Fisher MJ; Krasin MJ; Stewart CF; Broniscer A; Buchhalter I; Tatevossian RG; Orr BA; Neale G; Klimo P; Boop F; Srinivasan A; Pfister SM; Gilbertson RJ; Onar-Thomas A; Ellison DW; Northcott PA
    J Clin Oncol; 2021 Mar; 39(7):822-835. PubMed ID: 33405951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial.
    Robinson GW; Rudneva VA; Buchhalter I; Billups CA; Waszak SM; Smith KS; Bowers DC; Bendel A; Fisher PG; Partap S; Crawford JR; Hassall T; Indelicato DJ; Boop F; Klimo P; Sabin ND; Patay Z; Merchant TE; Stewart CF; Orr BA; Korbel JO; Jones DTW; Sharma T; Lichter P; Kool M; Korshunov A; Pfister SM; Gilbertson RJ; Sanders RP; Onar-Thomas A; Ellison DW; Gajjar A; Northcott PA
    Lancet Oncol; 2018 Jun; 19(6):768-784. PubMed ID: 29778738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort.
    Waszak SM; Northcott PA; Buchhalter I; Robinson GW; Sutter C; Groebner S; Grund KB; Brugières L; Jones DTW; Pajtler KW; Morrissy AS; Kool M; Sturm D; Chavez L; Ernst A; Brabetz S; Hain M; Zichner T; Segura-Wang M; Weischenfeldt J; Rausch T; Mardin BR; Zhou X; Baciu C; Lawerenz C; Chan JA; Varlet P; Guerrini-Rousseau L; Fults DW; Grajkowska W; Hauser P; Jabado N; Ra YS; Zitterbart K; Shringarpure SS; De La Vega FM; Bustamante CD; Ng HK; Perry A; MacDonald TJ; Hernáiz Driever P; Bendel AE; Bowers DC; McCowage G; Chintagumpala MM; Cohn R; Hassall T; Fleischhack G; Eggen T; Wesenberg F; Feychting M; Lannering B; Schüz J; Johansen C; Andersen TV; Röösli M; Kuehni CE; Grotzer M; Kjaerheim K; Monoranu CM; Archer TC; Duke E; Pomeroy SL; Shelagh R; Frank S; Sumerauer D; Scheurlen W; Ryzhova MV; Milde T; Kratz CP; Samuel D; Zhang J; Solomon DA; Marra M; Eils R; Bartram CR; von Hoff K; Rutkowski S; Ramaswamy V; Gilbertson RJ; Korshunov A; Taylor MD; Lichter P; Malkin D; Gajjar A; Korbel JO; Pfister SM
    Lancet Oncol; 2018 Jun; 19(6):785-798. PubMed ID: 29753700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.
    Goschzik T; Schwalbe EC; Hicks D; Smith A; Zur Muehlen A; Figarella-Branger D; Doz F; Rutkowski S; Lannering B; Pietsch T; Clifford SC
    Lancet Oncol; 2018 Dec; 19(12):1602-1616. PubMed ID: 30392813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time, pattern, and outcome of medulloblastoma relapse and their association with tumour biology at diagnosis and therapy: a multicentre cohort study.
    Hill RM; Richardson S; Schwalbe EC; Hicks D; Lindsey JC; Crosier S; Rafiee G; Grabovska Y; Wharton SB; Jacques TS; Michalski A; Joshi A; Pizer B; Williamson D; Bailey S; Clifford SC
    Lancet Child Adolesc Health; 2020 Dec; 4(12):865-874. PubMed ID: 33222802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis.
    Ramaswamy V; Remke M; Bouffet E; Faria CC; Perreault S; Cho YJ; Shih DJ; Luu B; Dubuc AM; Northcott PA; Schüller U; Gururangan S; McLendon R; Bigner D; Fouladi M; Ligon KL; Pomeroy SL; Dunn S; Triscott J; Jabado N; Fontebasso A; Jones DT; Kool M; Karajannis MA; Gardner SL; Zagzag D; Nunes S; Pimentel J; Mora J; Lipp E; Walter AW; Ryzhova M; Zheludkova O; Kumirova E; Alshami J; Croul SE; Rutka JT; Hawkins C; Tabori U; Codispoti KE; Packer RJ; Pfister SM; Korshunov A; Taylor MD
    Lancet Oncol; 2013 Nov; 14(12):1200-7. PubMed ID: 24140199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exclusive Hyperfractionated Radiation Therapy and Reduced Boost Volume for Standard-Risk Medulloblastoma: Pooled Analysis of the 2 French Multicentric Studies MSFOP98 and MSFOP 2007 and Correlation With Molecular Subgroups.
    Carrie C; Kieffer V; Figarella-Branger D; Masliah-Planchon J; Bolle S; Bernier V; Laprie A; Supiot S; Leseur J; Habrand JL; Alapetite C; Kerr C; Dufour C; Claude L; Chapet S; Huchet A; Bondiau PY; Escande A; Truc G; Nguyen TD; Pasteuris C; Vigneron C; Muracciole X; Bourdeaut F; Appay R; Dubray B; Colin C; Ferlay C; Dussart S; Chabaud S; Padovani L; ;
    Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1204-1217. PubMed ID: 32768563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subgroup and subtype-specific outcomes in adult medulloblastoma.
    Coltin H; Sundaresan L; Smith KS; Skowron P; Massimi L; Eberhart CG; Schreck KC; Gupta N; Weiss WA; Tirapelli D; Carlotti C; Li KKW; Ryzhova M; Golanov A; Zheludkova O; Absalyamova O; Okonechnikov K; Stichel D; von Deimling A; Giannini C; Raskin S; Van Meir EG; Chan JA; Fults D; Chambless LB; Kim SK; Vasiljevic A; Faure-Conter C; Vibhakar R; Jung S; Leary S; Mora J; McLendon RE; Pollack IF; Hauser P; Grajkowska WA; Rubin JB; van Veelen MC; French PJ; Kros JM; Liau LM; Pfister SM; Kool M; Kijima N; Taylor MD; Packer RJ; Northcott PA; Korshunov A; Ramaswamy V
    Acta Neuropathol; 2021 Nov; 142(5):859-871. PubMed ID: 34409497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New Approaches in Targeted Therapy for Medulloblastoma in Children.
    Maier H; Dalianis T; Kostopoulou ON
    Anticancer Res; 2021 Apr; 41(4):1715-1726. PubMed ID: 33813375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease.
    Hill RM; Kuijper S; Lindsey JC; Petrie K; Schwalbe EC; Barker K; Boult JK; Williamson D; Ahmad Z; Hallsworth A; Ryan SL; Poon E; Robinson SP; Ruddle R; Raynaud FI; Howell L; Kwok C; Joshi A; Nicholson SL; Crosier S; Ellison DW; Wharton SB; Robson K; Michalski A; Hargrave D; Jacques TS; Pizer B; Bailey S; Swartling FJ; Weiss WA; Chesler L; Clifford SC
    Cancer Cell; 2015 Jan; 27(1):72-84. PubMed ID: 25533335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relapse patterns in pediatric embryonal central nervous system tumors.
    Perreault S; Lober RM; Carret AS; Zhang G; Hershon L; Décarie JC; Yeom K; Vogel H; Fisher PG; Partap S
    J Neurooncol; 2013 Nov; 115(2):209-15. PubMed ID: 23921420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological and clinical heterogeneity of MYCN-amplified medulloblastoma.
    Korshunov A; Remke M; Kool M; Hielscher T; Northcott PA; Williamson D; Pfaff E; Witt H; Jones DT; Ryzhova M; Cho YJ; Wittmann A; Benner A; Weiss WA; von Deimling A; Scheurlen W; Kulozik AE; Clifford SC; Peter Collins V; Westermann F; Taylor MD; Lichter P; Pfister SM
    Acta Neuropathol; 2012 Apr; 123(4):515-27. PubMed ID: 22160402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes.
    Sharma T; Schwalbe EC; Williamson D; Sill M; Hovestadt V; Mynarek M; Rutkowski S; Robinson GW; Gajjar A; Cavalli F; Ramaswamy V; Taylor MD; Lindsey JC; Hill RM; Jäger N; Korshunov A; Hicks D; Bailey S; Kool M; Chavez L; Northcott PA; Pfister SM; Clifford SC
    Acta Neuropathol; 2019 Aug; 138(2):309-326. PubMed ID: 31076851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study.
    Schwalbe EC; Lindsey JC; Nakjang S; Crosier S; Smith AJ; Hicks D; Rafiee G; Hill RM; Iliasova A; Stone T; Pizer B; Michalski A; Joshi A; Wharton SB; Jacques TS; Bailey S; Williamson D; Clifford SC
    Lancet Oncol; 2017 Jul; 18(7):958-971. PubMed ID: 28545823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of Children's Oncology Group trial A9961.
    Packer RJ; Zhou T; Holmes E; Vezina G; Gajjar A
    Neuro Oncol; 2013 Jan; 15(1):97-103. PubMed ID: 23099653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk stratification of childhood medulloblastoma in the molecular era: the current consensus.
    Ramaswamy V; Remke M; Bouffet E; Bailey S; Clifford SC; Doz F; Kool M; Dufour C; Vassal G; Milde T; Witt O; von Hoff K; Pietsch T; Northcott PA; Gajjar A; Robinson GW; Padovani L; André N; Massimino M; Pizer B; Packer R; Rutkowski S; Pfister SM; Taylor MD; Pomeroy SL
    Acta Neuropathol; 2016 Jun; 131(6):821-31. PubMed ID: 27040285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci.
    Pfister S; Remke M; Benner A; Mendrzyk F; Toedt G; Felsberg J; Wittmann A; Devens F; Gerber NU; Joos S; Kulozik A; Reifenberger G; Rutkowski S; Wiestler OD; Radlwimmer B; Scheurlen W; Lichter P; Korshunov A
    J Clin Oncol; 2009 Apr; 27(10):1627-36. PubMed ID: 19255330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables.
    Ellison DW; Kocak M; Dalton J; Megahed H; Lusher ME; Ryan SL; Zhao W; Nicholson SL; Taylor RE; Bailey S; Clifford SC
    J Clin Oncol; 2011 Apr; 29(11):1400-7. PubMed ID: 20921458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploratory analysis of ERCC2 DNA methylation in survival among pediatric medulloblastoma patients.
    Banfield E; Brown AL; Peckham EC; Rednam SP; Murray J; Okcu MF; Mitchell LE; Chintagumpala MM; Lau CC; Scheurer ME; Lupo PJ
    Cancer Epidemiol; 2016 Oct; 44():161-166. PubMed ID: 27607585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.